Heartland Advisors Inc. Sells 309 Shares of Johnson & Johnson (NYSE:JNJ)

Heartland Advisors Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 1.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,281 shares of the company’s stock after selling 309 shares during the period. Heartland Advisors Inc.’s holdings in Johnson & Johnson were worth $4,872,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Hibernia Wealth Partners LLC acquired a new position in shares of Johnson & Johnson during the third quarter valued at $27,000. FNY Investment Advisers LLC acquired a new position in Johnson & Johnson during the 3rd quarter valued at about $37,000. Tower View Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 183.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 165 shares during the last quarter. Creative Capital Management Investments LLC grew its position in shares of Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after buying an additional 86 shares during the period. Finally, VitalStone Financial LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth approximately $48,000. Institutional investors own 68.40% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, January 24th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Wells Fargo & Company lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $170.00 to $163.00 in a research report on Wednesday, December 13th. Morgan Stanley cut their price target on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 24th. Finally, UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their target price for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Eight equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $176.14.

Read Our Latest Stock Report on JNJ

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $156.76 on Monday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.21 and a quick ratio of 0.96. The firm has a market cap of $377.37 billion, a price-to-earnings ratio of 11.35, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. Johnson & Johnson has a one year low of $144.95 and a one year high of $175.97. The stock’s 50-day moving average is $158.20 and its 200-day moving average is $158.73.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The firm had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. During the same quarter in the prior year, the firm posted $2.35 EPS. The business’s revenue was down 9.7% on a year-over-year basis. Equities analysts predict that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be given a dividend of $1.19 per share. The ex-dividend date is Friday, February 16th. This represents a $4.76 annualized dividend and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 34.47%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Further Reading

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.